Agenus Inc. (NASDAQ:AGEN) Receives $10.00 Consensus Price Target from Analysts

Agenus Inc. (NASDAQ:AGEN) has been given an average rating of “Hold” by the six analysts that are presently covering the stock, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $10.00.

Separately, HC Wainwright reiterated a “neutral” rating on shares of Agenus in a research report on Thursday, December 5th.

Agenus Trading Down 8.2 %

AGEN opened at $3.12 on Friday. Agenus has a 12 month low of $2.50 and a 12 month high of $19.69. The company has a market cap of $73.19 million, a PE ratio of -0.28 and a beta of 1.27. The company has a 50 day moving average of $3.20 and a 200 day moving average of $5.62.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Point72 DIFC Ltd bought a new stake in Agenus in the 2nd quarter worth approximately $51,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Agenus during the second quarter worth approximately $106,000. HighTower Advisors LLC lifted its holdings in shares of Agenus by 46.1% in the 3rd quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 7,530 shares during the last quarter. Exchange Traded Concepts LLC boosted its stake in shares of Agenus by 52.0% in the 3rd quarter. Exchange Traded Concepts LLC now owns 27,543 shares of the biotechnology company’s stock valued at $151,000 after purchasing an additional 9,422 shares in the last quarter. Finally, State Street Corp grew its holdings in shares of Agenus by 2.1% during the 3rd quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock valued at $2,563,000 after purchasing an additional 9,731 shares during the last quarter. Institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.